Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-22-013518
Filing Date
2022-08-12
Accepted
2022-08-12 16:46:25
Documents
84
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A nrxp-20210930x10qa.htm   iXBRL 10-Q/A 2106047
2 EX-10.1 nrxp-20210930xex10d1.htm EX-10.1 327665
3 EX-31.1 nrxp-20210930xex31d1.htm EX-31.1 15358
4 EX-31.2 nrxp-20210930xex31d2.htm EX-31.2 15422
5 EX-32.1 nrxp-20210930xex32d1.htm EX-32.1 7094
6 EX-32.2 nrxp-20210930xex32d2.htm EX-32.2 6416
7 GRAPHIC nrxp-20210930xex10d1001.jpg GRAPHIC 5644
  Complete submission text file 0001558370-22-013518.txt   9815686

Data Files

Seq Description Document Type Size
8 EX-101.SCH nrxp-20210930.xsd EX-101.SCH 87135
9 EX-101.CAL nrxp-20210930_cal.xml EX-101.CAL 42165
10 EX-101.DEF nrxp-20210930_def.xml EX-101.DEF 348177
11 EX-101.LAB nrxp-20210930_lab.xml EX-101.LAB 521450
12 EX-101.PRE nrxp-20210930_pre.xml EX-101.PRE 520071
78 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20210930x10qa_htm.xml XML 1628206
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38302 | Film No.: 221160831
SIC: 2834 Pharmaceutical Preparations